Kim Anne P, Baker Danial E, Levien Terri L
Consult Pharm. 2018 Apr 1;33(4):201-209. doi: 10.4140/TCP.n.2018.201.
To provide a review of tardive dyskinesia (TD) symptoms, etiology, pathophysiology, and treatments.
PubMed, Web of Science, ClinicalTrials. gov, and Google Scholar were searched for relevant literature using a combination of the following terms: tardive dyskinesia, treatment, management, guidelines, tetrabenazine, deutetrabenazine, and valbenazine. Sources were limited to human data.
STUDY SELECTION/DATA EXTRACTION: Articles were reviewed for relevance to TD therapy. Reference lists were manually searched for other relevant articles. Selected literature was published between 1968 and 2017.
This article reviews treatment options available for patients with TD. Many agents have been tried off-label to manage symptoms, with limited evidence of benefit. The Food and Drug Administration approved the first drug to treat TD valbenazine on April 11, 2017.
TD is largely iatrogenic. Valbenazine's approval by the Food and Drug Administration was followed by the approval of deutetrabenazine, a drug with similar mechanism of action. Further data from postmarketing studies will be needed to verify that valbenazine's adverse effect profile is different from the profiles of tetrabenazine and deutetrabenazine.
综述迟发性运动障碍（TD）的症状、病因、病理生理学及治疗方法。
使用以下术语组合在PubMed、科学网、ClinicalTrials.gov和谷歌学术上搜索相关文献：迟发性运动障碍、治疗、管理、指南、丁苯那嗪、氘代丁苯那嗪和缬苯那嗪。资料限于人类数据。
研究选择/数据提取：对文章进行相关性审查以确定其与TD治疗的相关性。手动检索参考文献列表以查找其他相关文章。所选文献发表于1968年至2017年之间。
本文综述了TD患者可用的治疗选择。许多药物已被用于非标签治疗以控制症状，但获益证据有限。2017年4月11日，美国食品药品监督管理局批准了首个治疗TD的药物缬苯那嗪。
TD主要是医源性的。继缬苯那嗪被美国食品药品监督管理局批准后，作用机制相似的药物氘代丁苯那嗪也获得批准。需要上市后研究的进一步数据来证实缬苯那嗪的不良反应情况与丁苯那嗪和氘代丁苯那嗪不同。
